Holen Sie sich die Stockscreener-App
0.9603
3.25%
0.0302
Schlusskurs vom Vortag:
$0.9301
Offen:
$0.9199
24-Stunden-Volumen:
630.81K
Relative Volume:
0.49
Marktkapitalisierung:
$103.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.65M
KGV:
-4.4213
EPS:
-0.2172
Netto-Cashflow:
$-14.43M
1W Leistung:
+6.58%
1M Leistung:
-5.85%
6M Leistung:
-32.37%
1J Leistung:
+83.75%
1-Tages-Spanne:
$0.9131
$0.9812
1-Wochen-Bereich:
$0.78
$0.9812
52-Wochen-Spanne:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
(403) 670-7377
Adresse
804, 322 - 11 AVENUE SW, CALGARY, AB
Compare ONCY vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9603 | 103.33M | 0 | -20.65M | -14.43M | -0.2172 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Eingeleitet | Lake Street | Buy |
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Oncolytics Biotech (NASDAQ:ONCY) Upgraded to Hold at Wall Street Zen - MarketBeat
Oncolytics Biotech: Financial Data Forecasts Estimates and Expectations | ONYN | US68237V1035 - MarketScreener
Oncolytics Biotech’s U.S. Move Resets Regulatory Path And Valuation Debate - sahmcapital.com
Oncolytics Biotech: Target Price Consensus and Analysts Recommendations | ONCY | US68237V1035 - marketscreener.com
Oncolytics Biotech Inc.: Financial Data Forecasts Estimates and Expectations | ONCY | US68237V1035 - MarketScreener
Oncolytics Biotech: Revenue and Earnings Analysts Forecasts Revisions | ONCY | US68237V1035 - MarketScreener
Oncolytics Biotech Inc.: Fundamental Analysis and Financial Ratings | ONCY | US68237V1035 - MarketScreener
ONCY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oncolytics Biotech Inc. (ONCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oncolytics Biotech Completes Domicile Change to the United States - MarketScreener
Stocks in play: Oncolytics Biotech Inc - Barchart
Oncolytics Biotech® Completes Domicile Change to the United States - Sahm
Oncolytics completes reincorporation from Canada to Nevada By Investing.com - Investing.com South Africa
Oncolytics Biotech | 10-K: FY2025 Annual Report - Moomoo
Oncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade Off - Yahoo Finance
Oncolytics Biotech Completes Domestication to Nevada with New Governance - TipRanks
Oncolytics (ONCY) Completes Move to US Incorporation - GuruFocus
Oncolytics Biotech (NASDAQ:ONCY) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Oncolytics Biotech Completes Move to U.S., Becomes Nevada Corporation and Sets San Diego as New Headquarters - Minichart
[8-K] ONCOLYTICS BIOTECH INC Reports Material Event - Stock Titan
Oncolytics shifts to Nevada as San Diego becomes new headquarters - Stock Titan
Oncolytics Biotech (ONCY) re-registers $139M; $250M shelf available - Stock Titan
ONCY SEC FilingsOncolytics Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Outlook: Is Oncolytics Biotech Inc undervalued by DCF analysis2026 Price Swings & Real-Time Volume Analysis - baoquankhu1.vn
[POS AM] ONCOLYTICS BIOTECH INC SEC Filing - Stock Titan
Aug Setups: Can Oncolytics Biotech Inc expand its profit margins2026 Geopolitical Influence & AI Forecasted Stock Moves - baoquankhu1.vn
Oncolytics Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Oncolytics Biotech (NASDAQ: ONCY) flags going concern and funding risk - Stock Titan
Sentiment Recap: Will Oncolytics Biotech Inc outperform the market in YEAR2026 Snapshot & Verified Momentum Stock Watchlist - baoquankhu1.vn
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Is It Time To Reassess Oncolytics Biotech (ONCY) After Recent Trial Progress News? - Sahm
Aug Closing: Is Oncolytics Biotech Inc stock a good dividend stock2026 Setups & Free Long-Term Investment Growth Plans - baoquankhu1.vn
If You Invested $1,000 in Oncolytics Biotech Inc (ONCY) - Stock Titan
Oncolytics Biotech Inc. Adopts New Articles and Notice of Articles Following Continuance to British Columbia Corporate Law - Minichart
Oncolytics Biotech completes first step of redomestication to British Columbia - Investing.com UK
Oncolytics Biotech completes first step of redomestication to British Columbia By Investing.com - Investing.com India
Form 8K Oncolytics Biotech Inc. For: 20 March By Investing.com - Investing.com South Africa
Form 8K Oncolytics Biotech Inc. For: 20 March - Investing.com
Oncolytics Biotech Shifts Corporate Domicile to British Columbia - TipRanks
Oncolytics Biotech (NASDAQ: ONCY) outlines move from Canada to Nevada - stocktitan.net
Oncolytics Biotech to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 - marketscreener.com
Oncolytics Biotech Shares Gain on Upcoming Clinical Data Presentations - AD HOC NEWS
Oncolytics Biotech® to Host Conference Call to Discuss Second Qu - GuruFocus
Oncolytics Biotech Showcases Pelareorep as Immune-Priming Backbone With New AACR 2026 Data - TipRanks
Oncolytics to present new data on Pelareorep at AACR 2026 - TipRanks
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - marketscreener.com
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
Oncolytics (ONCY) Presents Promising Cancer Research at AACR 202 - GuruFocus
Oncolytics Highlights New Pelareorep Data in Cancer Immunotherapy - TipRanks
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 - The Manila Times
Oncolytics Biotech (Nasdaq: ONCY) showcases new pelareorep immune-priming data at AACR 2026 - Stock Titan
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oncolytics Biotech Inc-Aktie (ONCY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
0.49%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):